7:00 a.m.

Registration and Continental Breakfast

8:00 a.m.

Welcome and Opening Remarks

8:15 a.m.

Kidney Paired Donation (KPD): How Is It Working? John J. Friedewald, MD, Northwestern University, Feinberg School of Medicine, ACPE #0012-9999-013-132-L04-P (K) 
The widening gap between the demand for and supply of donor kidneys has led to a call for an expansion in the potential donor pool. Efforts have been made to increase the number of available grafts by facilitating additional donations of living-donor kidneys. Such efforts include KPD, allowing for a significant increase in the number of patients that receive a living kidney transplant, which, in turn frees up additional deceased donor kidneys for those that are on the national wait list for a kidney. This presentation will provide an update of KPD and discuss the challenges faced and the next steps that will need to be initiated to maximize the potential benefit for patients who might receive transplants as a result of broadened KPD.

Objectives:

• Review the challenges with KPD and steps that are taken to maximize the potential benefit for patients who might receive transplants as a result of broadened KPD.
• Discuss the United Network for Organ Sharing (UNOS) pilot and their outcomes to date.
• Explain the importance of KPD and the significant impact it has in facilitating live-donor kidney transplantation.

9:15 a.m.

Ethics of Transplantation: Proposed Changes in Abdominal Organ Allocation, Dorry Segev, MD, PhD, Johns Hopkins Medicine, ACPE #0012-9999-013-138-L01-P (K) 
The supply of donor livers and kidneys does not meet the demand and is one of the greatest concerns for transplantation candidates, as well as a challenge for clinicians who treat them. According to the Organ Procurement and Transplant Network (OPTN), there were more than 16,000 Americans on the waiting list to receive a liver and 92,000 on the waiting list to receive a kidney in 2011. Experts have been meeting for the past two years to develop a modified liver allocation system that aims to reduce wait-list mortality. In addition, the UNOS has proposed certain kidney allocation policy changes that will help people who have better survival chances to get healthy kidneys.

This presentation will describe the proposed algorithm for liver distribution that, it is anticipated, would reduce the number of wait-list deaths with minimized travel distances for organs and would mitigate the crisscrossing of livers within a region. The proposed policy for kidneys, which will work on a kidney scoring system wherein a donor kidney will be allocated a certain score based on its viability and how long it is likely to function when transplanted, will also be discussed.

Objectives:

• Evaluate the proposed modified allocation systems for liver and kidney transplantation.
• Relate the process and rationale by which these proposed changes were reached and the ethical considerations involved in this process.

10:15 a.m.

Break

10:30 a.m.

Management of Ventricular Assist Devices (VADs), Mark L. Barr, MD, University of Southern California Keck School of Medicine, ACPE #0012-9999-013-134-L01-P (K) 
While the demand for heart transplantation has increased, the limited availability of hearts has remained constant. In order to bridge this gap, VADs are being used to enable patients to survive until a heart becomes available or in some cases, to extend the lives of patients who do not qualify for a heart transplant. Managing patients on chronic VAD support requires regular patient follow-up and multidisciplinary care teams. This presentation will review management strategies to reduce morbidity and mortality in heart failure patients supported chronically with VADs, and describe candidate selection, outpatient strategies to optimize device performance, complications that warrant close monitoring, heart failure management and currently available devices.

Objectives:

• Review management strategies to reduce morbidity and mortality in heart failure patients supported chronically with VADs.
• Describe candidate selection, outpatient strategies to optimize device performance and complications that warrant close monitoring.
• Provide an overview of the current ventricular assist devices available.

11:30 a.m.

Challenges of Pediatric Heart Transplantation, Beth D. Kaufman, MD, Lucile Packard Children's Hospital, ACPE #0012-9999-013-135-L01-P (K) 
Transplantation in children differs from adult transplantation. Not only are children smaller than adults, they also have special emotional and medical needs. So that children can reach their full potential, their care must be focused on the fact that they are constantly growing and developing. This presentation will review challenges facing health care professionals who care for pediatric solid organ transplant patients from a physical, psychosocial and behavioral perspective.

Objectives:

• Discuss strategies to prepare children for transplantation.
• Outline physical, psychosocial and behavioral challenges in pediatric transplantation.

12:15 p.m.

Lunch (provided)

1:15 p.m.

Lung Transplantation, Fernando Torres, MD, UT Southwestern Medical Center, ACPE #0012-9999-013-136-L01-P (K) 
Lung transplantation is a rapidly evolving field of pulmonary medicine. In addition, the system of organ allocation in the United States was overhauled in 2005, and the lung allocation score (LAS) was introduced. This overhaul changed the timing of when patients are listed for lung transplantation. It also increased the medical acuity of patients ultimately undergoing this procedure. Pulmonary rehabilitation aims to reduce symptoms, decrease disability, increase participation in physical and social activities, and improve the overall quality of life. This presentation will discuss the unique problems and needs of lung transplant patients and provide rehabilitation intervention strategies with the goal of improving long-term outcomes.

Objectives:

• Describe the rationale for the LAS system of organ allocation.
• Review pre- and posttransplant management strategies, to include pulmonary rehabilitation.
• Discuss whether a longer period of pulmonary rehabilitation would result in improving long-term outcomes.

2:00 p.m.

Liver Transplant for Patients With Hepatitis C, Anil Seetharam, MD, Banner Good Samaritan Medical Center, ACPE #0012-9999-013-137-L01-P (K) 
Hepatitis C virus (HCV)-associated cirrhosis is the most common indication for liver transplantation among adults. HCV infection remains a problem after transplantation and recurrent hepatic infection is the leading cause of graft failure. This presentation will summarize the results of transplantation for HCV, treatment of recurrence, the indications and contraindications for retransplantation, and the related prognosis.

Objectives:

• State the results of liver transplantation for HCV.
• Evaluate the indications and contraindications for retransplantation for patients with hepatitis C.
• Discuss novel therapies for the treatment of recurrence of this disease and the prognosis following re-transplantation.

3:00 p.m.

Break

3:15 p.m.

Intestinal Rehabilitation and Transplantation, David Mercer, MD, PhD, FRCS(C), University of Nebraska Medical Center, ACPE #0012-9999-013-133-L01-P (K)
Intestinal transplantation has evolved into an established therapeutic modality in the management of patients with irreversible intestinal failure. Intestinal failure is a highly disabling condition, and its diagnosis is life changing for both patients and their families. Although it is not uniformly fatal, if not properly managed, it could lead to serious, life-threatening complications. This presentation will review case studies on the optimal management of intestinal failure, including rehabilitation and transplantation.

Objectives:

• Review management strategies of intestinal failure, including rehabilitation and transplantation.
• Discuss the cost savings of providing total parenteral nutrition in the home.

4:15–5:00 p.m.

The Role of Pharmacogenomics in the Future of Health Care, Mary W. Roederer, PharmD, BCPS, University of North Carolina, ACPE #0012-9999-013-139-L04-P (K) 
Pharmacogenomics is the study of genetic variations that influence each individual’s response to drugs. The identification of genetic factors that influence drug absorption, metabolism, and action at the receptor level should, in theory, allow for individualized therapy, holding the promise that drug therapy might one day be personalized to reflect each person’s unique genetic makeup. Despite the promise of pharmacogenetics in potentially increasing drug efficacy and safety, the era of widespread application of pharmacogenomics has not yet arrived. This presentation will provide an overview of the current status of pharmacogenomics, the challenges this field faces and its likely evolution over the next several years.

Objectives:

• Describe the current status of pharmacogenetics and the changes we expect to see over the next several years.
• Identify the challenges and/or barriers that must be overcome before pharmacogenetic testing (genotyping) has a major impact on mainstream clinical medicine.

5:00–7:00 p.m.

Complimentary Get-Acquainted Reception
Join your colleagues for hors d’oeuvres and beverages. You won’t want to miss this opportunity to gather information and ideas from exhibitors regarding the management of complex medical conditions.

7:30 a.m.

Registration and Continental Breakfast

8:00 a.m.

Opening Remarks

8:15 a.m.

An Overview of Stem Cell Transplantation (SCT), Michael R. Bishop, MD, The University of Chicago Medicine, ACPE #0012-9999-013-140-L01-P (K) 
As SCT continues to grow and evolve, managing the continuum of care for these patients can be a unique challenge for clinicians. With increased emphasis on patient outcomes and the demand for quality, health care professionals look for guidelines that will facilitate optimal outcomes for their patients. This presentation will review key concepts of SCT; the role of the National Marrow Donor Program (NMDP); the different sources, types, and indications for SCT; as well as the potential complications, including infection and graft-versus-host disease (GVHD) with SCT.

Objectives:

• Define and explain the different types of blood/marrow transplants, sources of stem cells and adult diseases commonly treated with SCT.
• Describe GVHD, graft-versus-tumor effect, graft-versus-leukemia effect, remission and chemo-sensitive disease.
• Discuss potential general complications of SCT to include infection and organ failure.
• Review role of the NMDP in blood and marrow transplantation.

9:30 a.m.

Break

9:45 a.m.

Novel Agents for Graft-Versus-Host Disease (GVHD), John Koreth, MD, PhD, Dana-Farber Cancer Institute, ACPE #0012-9999-013-141-L01-P (K) 
Acute and chronic GVHD are potentially lethal complications after stem cell transplantation. Steroids are the appropriate first-line treatment for both. However, if patients do not adequately benefit from steroid therapy, mortality is high. This presentation will review treatment strategies for patients suffering from acute or chronic steroid-refractory GVHD while maintaining the graft-versus-tumor effect to avoid a potential rise in relapse-related mortality.

Objectives:

• Discuss treatment strategies for patients suffering from acute or chronic steroid-refractory GVHD while maintaining the graft-versus-tumor effect to avoid a potential rise in relapse-related mortality.

10:30 a.m.

Managing and Monitoring Posttransplant Patients, Asad Bashey, MD, PhD, The Blood and Marrow Transplant Program at Northside Hospital, ACPE #0012-9999-013-142-L01-P (K) 
After transplantation, infections, regimen-related toxicities, GVHD, veno-occlusive disease, and thrombotic microangiopathy are a few of the serious complications that are causes of expected mortality and morbidity in patients undergoing SCT. Recognizing complications early, while there are more therapeutic options and while treatments are more effective, is critical to the well-being of transplant recipients. This presentation will review the complications from SCT and explain how clinical laboratory monitoring may contribute to early diagnosis and treatment of the complications, resulting in prevention of the adverse events.

Objectives:

• List serious complications that are causes of expected mortality and morbidity in SCT patients.
• Discuss how clinical laboratory monitoring may contribute to early diagnosis and treatment of the complications from SCT, resulting in prevention of the adverse events.

11:15 a.m.

Stem Cell Transplantation for Pediatric Solid Tumors, Alix E. Seif, MD, MPH, The Children’s Hospital of Philadelphia, ACPE #0012-9999-013-143-L01-P (K) 
While advances in the treatment of pediatric cancers have increased cure rates, children with metastatic or recurrent solid tumors still have a dismal prognosis despite initial transient responses to therapy. SCT is frequently used to treat patients with other high-risk diseases, such as Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms’ tumor, retinoblastoma, germ-cell tumors, lymphomas and brain tumors. This presentation will discuss the evolving role of SCT for the treatment of pediatric solid tumors.

Objectives:

• Discuss the role of SCT for the treatment of pediatric solid tumors.
• Compare and contrast conventional chemotherapy and SCT regarding overall survival, long-term consequences of SCT, and quality of life.

12:00 p.m.

Luncheon Presentation—An Overview of OptumHealth™ (optional)
OptumHealth features best-in-class programs and services in case management, disease management, treatment of complex medical conditions, decision support, physical medicine and wellness. Learn about the products and services available through OptumHealth that can help payers and employers aggressively manage costs while enhancing members’/employees’ health and well-being.

1:30 p.m.

Myelodysplastic Syndromes (MDS), Ruben Mesa, MD, FACP, Mayo Clinic, ACPE #0012-9999-013-144-L01-P (K) 
Myelodysplastic syndromes encompass a series of hematologic conditions characterized by chronic cytopenias (anemia, neutropenia, thrombocytopenia) accompanied by abnormal cellular maturation. As a result, patients with MDS are at risk for symptomatic anemia, infection, and bleeding, as well as progression to acute myeloid leukemia (AML), which is often refractory to standard treatment. This presentation will provide an update on the International Prognostic Scoring System (IPSS) for MDS, treatment options and outcomes for MDS.

Objectives:

• Describe the clinical manifestations, diagnosis and treatment of myelodysplastic syndromes.
• Review the International Prognostic Scoring System (IPSS) for MDS.

2:15 p.m.

Acute Myeloid Leukemia (AML), Celalettin Ustun, MD, University of Minnesota, ACPE #0012-9999-013-145-L01-P (K) 
Twenty–30 percent of young-adult patients and 50 percent of older-adult patients with newly diagnosed AML will fail to attain a complete response (CR) with intensive induction chemotherapy due to drug resistance or death. In addition, a percentage of patients who initially attain a CR will relapse. This presentation will review treatment options for patients with AML who have failed to enter into CR or who have relapsed after attainment of a CR.

Objectives:

• Review treatment options for AML patients who have failed to achieve a CR or who have relapsed after attainment of a CR.
• Identify who should be transplanted, and state the risks for relapse.

3:00 p.m.

Break

3:15 p.m.

Malignancy After Stem Cell Transplantation, Shalini Shenoy, MD, St. Louis Children's Hospital, ACPE #0012-9999-013-146-L01-P (K)  
The success of SCT has led to the unfortunate complication of secondary malignancies in patients who would otherwise be long-term survivors. SCT survivors are at risk of developing therapy-related complications that may present years after treatment. These complications have surfaced as significant causes of increased mortality, and screening for some of these entities is advised in the hope that early detection may lead to better management. This presentation will discuss the importance of ongoing evaluation of the long-term SCT survivor.

Objectives:

• Discuss posttransplant malignancies in the SCT survivor, such as solid tumors, acute leukemia, myelodysplastic syndromes, and posttransplant lymphoproliferative disease (PTLD).
• Review screening methods and the importance of ongoing evaluation for the long-term survivor.

4:00–5:00 p.m.

Genetic Counseling and Cancer, Robin L. Bennett, MS, CGC, DSc (Hon), University of Washington School of Medicine, ACPE #0012-9999-013-147-L01-P (K) 
Every day, researchers are learning more about the genetics of common diseases and how those diseases run in families. If you have an inherited disease in your family, a genetic counseling session can help you understand your personal risk or the risk for other family members. It can also help you learn which testing, surveillance, prevention strategies or research trials may be right for your situation. This presentation will outline how genetic counselors work as part of a health care team in conjunction with specially trained doctors, social workers, nurses, medical geneticists or other specialists to help families make informed decisions about their health.

Objectives:

• Describe the role of a genetic counselor.
• Discuss what to expect from a genetic counseling session.
• Identify clues in a family history suggesting an increased risk of various types of cancer.
• Describe strategies for recording a medical family history.

7:30 a.m.

Registration and Continental Breakfast

8:00 a.m.

Opening Remarks

8:15 a.m.

Palliative Care for the Pediatric Patient, Richard Goldstein, MD, Dana-Farber Cancer Institute, Boston Children’s Hospital, ACPE #0012-9999-013-159-L01-P (K) 
Palliative care for children aims to improve quality of life for the pediatric patient as well as for his or her family. This is done through expert management of pain and other physical as well as the emotional and spiritual support services, offering the patient and family specialized counseling to help them cope with the roller coaster of emotions that result from dealing with a serious illness or condition. This presentation will focus on prevention and relief of suffering, regardless of the stage of disease, and comprehensively addresses the physical, psychosocial, or spiritual needs of the child and family.

Objectives:

• Describe how interdisciplinary teams can help ensure that the emotional, spiritual, physical, and practical needs of children and families are identified.
• Discuss age-appropriate communication techniques for the pediatric patient dealing with a serious illness or condition.
• Review challenges with pain management for pediatric patients.

9:00 a.m.

What’s New in Colorectal Cancer Research and Treatment? George A. Fisher, Jr., MD, PhD, Stanford Hospital & Clinics, ACPE #0012-9999-013-149-L01-P (K) 
Research continues in the area of colorectal cancer. Scientists are looking for causes and ways to prevent colorectal cancer, as well as ways to improve treatments. Colorectal cancer is much easier to treat effectively if it is found at a very early stage, but only about half of Americans age 50 or older have had any colorectal cancer screening at all. This presentation will look at the effectiveness of current colorectal cancer screening methods and current treatment options, to include surgical techniques and the advances in targeted and immunotherapy.

Objectives:

• Explore prognostic indicators for a long-term prognosis for both colon and rectal cancer.
• Discuss the effectiveness of current colorectal cancer screening methods.
• Review current treatment options to include surgical techniques and the advances in targeted and immunotherapy.

10:00 a.m.

Break

10:15 a.m.

Surgical Oncology, David R. Byrd, MD, FACS, University of Washington School of Medicine, ACPE #0012-9999-013-150-L01-P (K) 
When metastatic disease is limited to an organ-specific site, an important consideration is whether the disease is resectable at the time of initial diagnosis or whether it is initially deemed to be unresectable but may become resectable with the up-front use of chemotherapy. With the integration of chemotherapy and surgical resection, overall five-year survival rates on the order of 30–40 percent can now be achieved. This presentation will explore the importance of a multidisciplinary, team-based approach and the role of surgeons, medical oncologists, radiologists, and other health care professionals in the treatment of cancer.

Objectives:

• Discuss surgical considerations for patients with metastatic disease.
• Determine the optimal timing and sequence of surgery and chemotherapy.

11:00 a.m.

Management of the Long-Term Breast Cancer Survivor, Elizabeth A. Kvale, MD, University of Alabama at Birmingham, ACPE #0012-9999-013-151-L01-P (K) 
In the United States, there were an estimated 14 million cancer survivors as of 2012, a figure that is expected to increase to approximately 18 million in the next 10 years. Nearly 3 million women have a history of breast cancer and constitute over 40 percent of female cancer survivors. This presentation will discuss the unique medical and psychosocial needs of breast cancer survivors and the resources that can assist patients, caregivers, and health care providers in navigating the various phases of cancer survivorship.

Objectives:

• Discuss the unique medical and psychosocial needs of breast cancer survivors.
• Review the resources that can assist patients, caregivers, and health care providers in navigating the various phases of cancer survivorship.

12:00 p.m.

Lunch (provided)

1:00 p.m.

Cancer Pain Management: Finding the Best Treatment for Patients, Sharon Weinstein, MD, FAAHPM, Huntsman Cancer Institute at the University of Utah, ACPE #0012-9999-013-152-L01-P (K) 
Optimal supportive care for the cancer patient requires an interdisciplinary approach that encompasses pain management, end-of-life issues and psychological support. This presentation will describe the etiology of cancer-related pain and address the importance of pain management to help relieve or prevent suffering and improve patients’ quality of life.

Objectives:

• Summarize the types and causes of cancer pain and their treatment.
• Discuss management of the pain caused by cancer and its treatment.
• State barriers to the management of pain and fatigue in cancer patients.
• Outline pain assessment, as well as pharmacologic and nonpharmacologic management strategies of pain.

2:00 p.m.

Break

2:15 p.m.

Malignant Melanoma: Advances in Adjuvant Therapy and Treatment of Metastatic Disease, Alissa Marr, MD, University of Nebraska Medical Center, ACPE #0012-9999-013-158-L01-P (K) 
Although the incidence of malignant melanoma is increasing, most cases are diagnosed at an early stage, during which surgical excision is often curative. However, a minority of patients will present with metastatic disease or go on to develop metastases after their initial treatment. This presentation will review the current approach of treatments, as well as key factors in choosing a therapeutic approach, for the patient with advanced melanoma.

Objectives:

• Provide an overview of treatment options for malignant melanoma.
• State the key factors in choosing a therapeutic approach for the patient with advanced melanoma.

3:15 p.m.

Adolescent and Young-Adult Oncology, Jennifer Reichek, MD, MSW, Ann & Robert H. Lurie Children’s Hospital of Chicago, ACPE #0012-9999-013-154-L01-P (K) 
Adolescent and young adults are a distinct patient population within oncology, and they have different needs from other cancer patients. Oncology research and clinical agendas are not always designed to focus on the unique biological, clinical, psychosocial, and survivorship issues of the adolescent and young adult. This presentation will address adolescent and young-adult cancer care through interdisciplinary research, education, communication, and collaboration among health professionals.

Objectives:

• Discuss innovative models to implementing multidisciplinary care for adolescents and young adults with cancer.
• Examine transition of care issues for young-adult survivors of childhood and adolescent cancer.

4:00 p.m.

Adjourn